Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme (1 selected)

Guidance programme

Showing 51 to 75 of 342

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448Technology appraisal guidance
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]Technology appraisal guidanceTBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]Technology appraisal guidanceTBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Technology appraisal guidanceTBC
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]Technology appraisal guidanceTBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]Technology appraisal guidanceTBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Technology appraisal guidance
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Technology appraisal guidanceTBC
Colon cancer (adjuvant) - irinotecan [ID379]Technology appraisal guidanceTBC
Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]Technology appraisal guidanceTBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Technology appraisal guidanceTBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Technology appraisal guidanceTBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]Technology appraisal guidance
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]Technology appraisal guidance
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Technology appraisal guidanceTBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]Technology appraisal guidanceTBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]Technology appraisal guidanceTBC
DCVax-L for treating glioblastoma [ID836]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All